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Abstract HIV-1 affects tens of millions of people worldwide. Current treat-
ments often involve a cocktail of antiretroviral drugs, which are effective in
reducing the virus and extending life spans. However, there is currently no
FDA-approved HIV-1 transcription inhibitor. Furthermore, there have only
been a few attempts to model the transcription process in HIV-1. In this
work, we extend a novel three-state model of HIV-1 transcription introduced
in (DeMarino et al., 2020) that has been developed and validated against ex-
perimental data. After fitting this model to in vitro data, significant differences
in the transcription process of HIV-1 in T-cells and macrophages have been
observed. In particular, the activation of the HIV-1 promoter in T-cells ap-
pears to take place rapidly as the Tat protein approaches a critical threshold.
In contrast, the same process occurs smoother in macrophages.
In this work, we carry out systematic mathematical analyses of the model
to complement experimental data fitting and sensitivity analysis performed
earlier. We derive explicit solutions of the model to obtain exact transcription
process decay rates for the original model and then study the effect of nonlin-
earity on the system behavior, including the existence and the local and global
stability of the positive equilibrium. We were able to show the stability of the
positive steady state in limiting cases, with the global stability in the general
case remaining an open question.
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By modeling the effect of transcription-inhibiting drug therapy, we pro-
vide a nontrivial condition for it to be effective in reducing viral load. More-
over, our numerical simulations and analysis point out that the effect of the
transcription-inhibitor can be enhanced by synchronizing with standard treat-
ments, such as combination antiretroviral therapy, to allow the reduction of
total dosages and toxicity.
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1 Introduction
The Human Immunodeficiency Virus Type I (HIV-1) is the causative agent
of acquired immune deficiency syndrome (AIDS). Since the advent of combi-
nation antiretroviral therapy (cART) in the early 1990s, infected individuals
are living longer, healthier lives and transmission rates have slowed down.
However, of the 36.9 million infected worldwide, only 21.7 million people were
reported to be accessing cART and even fewer were maintaining the strict
adherence required by the therapy (UNAIDSDate, 2019). Current cART reg-
imens have been developed to target HIV-1 at almost every stage of the viral
life cycle. These include fusion/entry inhibitors which target HIV-1 cellular
receptors and associated viral proteins, reverse transcriptase inhibitors which
prevent the production of viral DNA from RNA, integrase inhibitors that func-
tion to mitigate integration of the virus into host DNA, and protease inhibitors
which block maturation of viral proteins. The combination of several inhibitors
is effective in lowering viral titers and reducing morbidity and mortality in in-
fected individuals (Heaton et al., 2010; Deeks et al., 2013; Mothobi and Brew,
2012). However, to date, there are no FDA-approved antiretrovirals that target
HIV-1 transcription. This therapeutic gap leads to persistent, low-level viral
transcription despite suppressive treatment, a concept which has been termed
“leaky latency”, resulting in approximately 1 × 103 copies of cell-associated
viral RNA in infected cells (Furtado et al., 1999; Hatano et al., 2012; Kumar
et al., 2007). While viremia is adequately controlled (< 50 viral RNA/mL),
cell-associated viral RNA can contribute to chronic inflammation, rapid viral
rebound, immune dysfunction via direct mechanisms, stochastic production of
viral proteins, or via release of viral RNA in extracellular vesicles (McCauley
et al., 2018; Akiyama et al., 2018; Ferdin et al., 2018; Narayanan et al., 2013;
Sampey et al., 2016; DeMarino et al., 2018; Hladnik et al., 2017; Li et al.,
2016b; Henderson et al., 2019).
Despite the presence of cART, HIV-1 can persist in viral reservoirs includ-
ing long-lived memory CD4+ T-cells, blood-brain barrier protected myeloid
cells of the central nervous system (CNS), and low cART penetration lymphoid
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tissues such as lymph nodes and gut-associated lymphoid tissue (GALT) (Sen-
gupta and Siliciano, 2018; Li et al., 2016a; Garrido and Margolis, 2015; Dave
et al., 2018; Hatano et al., 2013). These reservoirs can be maintained through
several mechanisms including chromatin modifications and blocks in viral tran-
scription initiation and elongation. Although HIV-1 can persist in a latent state
for long periods, activation of latently infected cells through antigen stimula-
tion or cytokine activation can lead to the induction of HIV-1 transcription
factors such as nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) or nuclear factor of activated T-cells (NFAT). Production of these
transcription factors can, in turn, cause viral reactivation of the latent provirus
leading to transcription of the HIV-1 genome and subsequent production of
viral proteins (Chou et al., 2013; Mbonye and Karn, 2014; Kumar et al., 2014).
Importantly, activation of the virus elicits cytolysis and immune-mediated re-
sponses to clear the virus. This mechanism has led to the development of a
therapeutic strategy termed “shock and kill”, an approach which takes aim at
latency-mediating mechanisms, such as histone deacetylases (HDACs) (Archin
et al., 2009; Lehrman et al., 2005; Wei et al., 2014), using latency-reversing
agents (LRAs) to reactivate and promote immune clearance of the virus. Con-
versely, others have proposed an opposite strategy known as “lock and block”
which focuses on promoting an inactive state of the HIV-1 LTR to inhibit vi-
ral transcription and virion production through the use of latency promoting
agents (LPAs). These studies have led to the identification of several HIV-
1 transcription inhibitors which have shown success in vitro, in vivo, and in
clinical trials (Mousseau et al., 2012, 2015; Kim et al., 2016; Jean et al., 2017;
Kessing et al., 2017; Rutsaert et al., 2019; Hayashi et al., 2017).
While there is a rich literature of mathematical modeling for HIV-1 trans-
mission at the population level (Eaton et al., 2012; Omondi et al., 2018;
Velasco-Hernandez et al., 2002; Li et al., 2018) and its interaction with the im-
mune system with or without treatments (Perelson and Nelson, 1999; Wodarz
and Nowak, 2002; Wang et al., 2016; Adak and Bairagi, 2018), mathematical
models at the molecular level for HIV-1 are far and few between. More recently,
Chavali et al. (2015) developed and showed that a multi-state promoter HIV-1
model is perhaps better at capturing the heterogeneous reactivation of HIV-
1 in response to treatments (e.g. “shock and kill” therapy) compared to the
single-state promoter model. Ke et al. (2015) also used a multi-state promoter
model to study the effect of Vorinostat, a drug used in the activation of HIV-1
transcription, with experimental data. Additionally, Gupta and Dixit (2018)
utilized a multi-state promoter model to study the synergy in combination of
latency-reversing therapies using stochastic simulation.
In prior work, we have developed a three-state LTR model of HIV-1 tran-
scription (DeMarino et al., 2020). This model evaluates various states of the
HIV-1 LTR, repressed (LTRR), intermediate (LTRI), and activated (LTRA)
in response to various stimuli including transcription inducers. Furthermore,
we modeled the transcription of two viral RNAs; a short non-coding RNA
trans-activation response (TAR) element, and genomic RNA (env), as well as
levels of viral proteins Tat (trans-activator of transcription), Pr55, and p24 in
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response to changes in the LTR state. This model has been validated in two
types of immune cells, T-cells, and myeloids, using biochemical assays which
assess each parameter and model predictions at extended time frames. In con-
trast to the model by Chavali et al. (2015), DeMarino et al. (2020) took into
account that the production of Tat, an early HIV-1 protein, only occurs dur-
ing the intermediate activation state, while genomic RNA produced during the
activated state is used to facilitate the production of viral particles. The sim-
ple structure of the model allows for direct incorporation of various therapies,
which potentially serves as a valuable tool in evaluating viral transcription in
response to various stimuli including LRAs and LPAs.
In this work, we carry out systematic mathematical analyses of the previous
model to show its biological and mathematical validity. The original model for-
mulation utilizes a switching function to model the Tat-dependent functional
responses, which limits the ability of the model to characterize differences
in the transcriptional behaviors in T-cells and macrophages. Additionally, it
leads to a discontinuity, which may not be biologically relevant. To address this
issue, we extend the model to consider continuous Tat-dependent functional re-
sponses. Similarly, we carry out mathematical analyses and data fitting for the
new model. We provide stability results in several limiting cases; however, the
global stability of the positive steady state in the general case is still an open
question. By comparing the two models (switching vs. continuous response),
we find observations that provide insights into the transcription process of
HIV-1. Specifically, there is a clear distinction in the transcriptional behaviors
between T-cells and macrophages, which is dependent on the amount of Tat
protein. Finally, we use the model to study the effectiveness of an experimental
transcription-inhibitor drug. Our results suggest that the Tat peptide mimetic
transcriptional inhibitor (F07#13) is synchronous with standard treatment.
Thus, by combining F07#13 with standard treatment such as cART, the total
dosage and the potential side effects may be reduced.
The remainder of this paper is organized as follows. In section 2, we briefly
introduce the mathematical model and describe how some treatments of HIV-
1 are incorporated into the model. In section 3, we carry out the study of the
properties of the model and its extension. The main goal is to demonstrate
that the model exhibits the expected biological dynamics, which entails the
analyses of positive invariance, boundedness and stability of solutions. Uti-
lizing experimental data in DeMarino et al. (2020), we carry out parameter
estimation to differentiate the dynamics between T-cells and macrophages in
section 4. An important novelty of the model is its ability to incorporate mul-
tiple treatments of HIV-1. Therefore, in section 5, we study the effect of the
transcriptional inhibitor F07#13 in combination with other drugs. Finally, we
discuss our results in section 6. Derivation of closed form solution of the lin-
ear model and details of numerical parameter estimation are provided in the
Appendix.
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2 Mathematical model
In DeMarino et al. (2020), the following three-state HIV-1 model of the tran-
scription process was derived and validated against experimental data in T-
cells and macrophages.
Fig. 1 HIV-1 transcription model. Three States of LTR, e.g. repressed (LTRR), intermedi-
ate (LTRI), activated (LTRA). The long and short RNA (envI , envA and TAR), Tat, Pr 55
and p24 interactions. The figure is adapted from DeMarino et al. (2020) under a Creative
Commons Attribution (CC BY) license.
d
dt
LTRR = kOFFLTRI − kONLTRR (1)
d
dt
LTRI = −
[
w3w4
w5
kA(Tat) + kOFF
]
LTRI + w1kILTRA + kONLTRR(2)
d
dt
LTRA =
w3w4
w5
kA(Tat) LTRI − w1kILTRA (3)
d
dt
Tat = αp1env I − γp1Tat (4)
d
dt
TAR = αm1,RLTRR + αm1,ILTRI + αm1,ALTRA − γm1TAR (5)
d
dt
env I = αm2,ILTRI − (γm,2 + αp1 + αp2) env I (6)
d
dt
envA = fm2(Tat)LTRA − (γm,2 + αp2) envA (7)
d
dt
Pr 55 = αp2env I + αp2envA − (αp3/w2)Pr55 (8)
d
dt
p24 = (αp3/w2)Pr55 − γp2p24 (9)
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The model incorporates important features of the basal and activated tran-
scription of the HIV-1 genome. The Long Terminal Repeat (LTR) is catego-
rized into three stages, suppressed (LTRR), intermediate (LTRI) and activated
(LTRA), similar to that of the model in Chavali et al. (2015). The ‘OFF’ states
refer to the repressed and intermediate HIV-1 promoters, while the ‘ON’ state
refers to the activated HIV-1 promoter. Here, kON , kOFF , kA(Tat) and kI are
transition rates from one state of LTR to another as indicated in Figure 1.
The total LTR is assumed to be conserved, so each LTR state in the model
represents the proportion of LTR in the respective state.
Another key feature of the model is the division of viral RNA into short-
non-coding RNA and long-genomic RNA, which are characterized by the
amount of TAR and env, respectively. The model further divides the env ac-
cording to its promoter LTR state, or env I and envA corresponding to LTRI
and LTRA, respectively. Additionally, TAR is produced by all three states of
LTR, but generally at different rates. Tat is produced via the translation of a
multiply-spliced mRNA, which is represented in the model as the transition
from env I to Tat. The presence of Tat directly affects the activation rate of
the intermediate LTR state. Hence, The coefficient kA(Tat) is expected to de-
pend on the level of Tat. Due to the quick transition to the active state, this
can be approximated as a step function or a Hill function (see Section 3). The
value of Tatcrit is the estimated number of Tat required to overcome poten-
tial sequestration by TAR in the cytoplasm to allow for efficient Tat-activated
transcription. Tat further enhances the transcription rate of activated LTR
to produce envA. This rate can also be represented by a Hill function with
the same Tatcrit value as kA(Tat). Finally, both env I and envA are used to
produce the HIV-1 gag polyprotein, Pr 55. Following its production, Pr 55 is
cleaved into smaller proteins, one of which is p24, which forms the capsid and
is tractable experimentally. Additional details on the parameter values are
listed in Table 1.
One of the novel usages of this model is its ability to incorporate and
study the effects of different drugs (DeMarino et al., 2020). In the model,
the parameter wi (i = 1,2,3,4,5) refers to the effect of different drugs on the
transcriptional dynamics of HIV-1. The current form of the model shows a
possibility of incorporating multiple drugs to study their effect in combina-
tion with each other (w2 - cART, w3 - IR, w4 PMA/PHA); however, for this
work, we will focus on a particular drug F07#13. The drug F07#13, a Tat
peptide mimetic, was developed to inhibit the transcription of HIV-1 virus
by inhibiting Tat transactivation of the HIV-1 promoter, thereby encouraging
the reverse direction from LTRA to LTRI and suppressing the activation of
LTRI (Lin et al., 2017; Van Duyne et al., 2013). In the model, these effects
are represented by the parameters w1 and w5, respectively.
The model is used with the following initial conditions: LTRR = 1 (or
100%) and LTRI = LTRA = 0, which means that we assume that all LTRs
are in the repressed state initially. Also, RNA1 = 0, RNA2I = 0, RNA2A = 0,
Tat = 0, Pr 55 = 0 and p24 = 0 at t = 0.
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Unit definition T-Cell macrophages
kON [H1 pc/mL/hr] LTRR → LTRI 5.785% 9.245%
kOFF [H1 pc/mL/hr] LTRI → LTRR 1.220% 1.228%
kA(Tat) [H1 pc/mL/hr] LTRI → LTRA 3.409% 9.010%
kI [H1 pc/mL/hr] LTRA → LTRI 0.0% 2.451%
αm1,R [copies/mL/hr] LTRR → TAR 2.50× 104 2.90× 104
αm1,I [copies/mL/hr] LTRI → TAR 2.80× 108 7.54× 104
αm1,A [copies/mL/hr] LTRA → TAR 1.37× 107 4.51× 105
αm2,I [copies/mL/hr] LTRI → envI 3.63× 105 8.13× 103
αm2,A [copies/mL/hr] LTRA → envI 2.47× 106 4.00× 104
αp1 [Tat dc/mL/hr] TAR→ Tat 0.040% 0.038%
αp2 [Pr 55 dc/mL/hr] TAR→ Pr 55 0.154% 0.194%
αp3 [p24 dc/mL/hr] Pr 55→ p24 0.136% 0.081%
γp1 [Tat/mL/hr] Tat degradation 0
∗ 0∗
γp2 [P24/mL/hr] p24 degradation 0
∗ 0∗
γm,1 [TAR/mL/hr] TAR degradation 1.17× 104 2.68× 104
γm,2 [envI/mL/hr] envI degradation 2.24× 103 5.91× 102
Tatcrit [Tat] switching limit 3001 3001
va unitless folds of increasing 150 150
Table 1 Table of parameters adapted from DeMarino et al. (DeMarino et al., 2020). Here,
“pc” - phosphorylation change, “dc” - densitometry change. DeMarino and colleagues as-
sumed the degradation rates for Tat and p24 are taken to be 0∗ for short period of time,
but for our analytical purpose, we will assume them to be strictly positive.
3 Dynamical system analysis
3.1 Global stability in case of piecewise constant switching rate fm(Tat) and
constant activation rate kA
In DeMarino et al. (DeMarino et al., 2020), the following assumptions were
made for activation rate kA and switching rate fm(Tat):
fm2(Tat) =
{
αm2,A/va if Tat < Tatcrit
αm2,A if Tat ≥ Tatcrit (10)
kA = const (11)
In this section we study stability of the corresponding linear dynamical
system.
We can see that the system (1)-(9) allows for the zero steady state, which
is always unstable assuming at least one of the LTRs is positive initially. This
is due to the conservative property of LTRs, so if at least one of the LTR
states starts out positive, all three states will be positive for all positive time,
see Appendix 7.1. This brings our focus to the the more interesting positive
steady state of the system. It is straightforward to show that all the eigenvalues
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are real for any values of the parameters, see Section 7.5. This motivates the
following theorem.
Theorem 1 The system (1)-(9) under assumptions (10)-(11) has a unique
asymptotically stable equilibrium, which is explicitly given in Appendix 7.2.
We prove stability in two steps. First, we decouple the system and use
Bendixon-Dulac criterion to show that the isolated (decoupled) system of
LTRs (LTRR,LTRI ,LTRA) has a unique positive steady state that is globally
asymptotically stable. It then follows directly that the entire system shares
the same property.
Proposition 1 The system (1)-(3) of LTR (i.e. LTRR,LTRI ,LTRA) under
assumptions (10)-(11) has a unique positive steady state that is globally asymp-
totically stable.
Proof First, note that ddt [LTRR + LTRI + LTRA] = 0, so the system of LTRs
decoupled from the rest of the equations has a conservation law and the bound-
edness of LTRR,LTRI ,LTRA follows immediately. We consider the reduced
two-dimensional system:
d
dt
[LTRI ] = kON − (kA + kOFF + kON )LTRI + (kI − kON )LTRA (12)
d
dt
[LTRA] = kALTRI − kILTRA (13)
The nullclines of LTRI and LTRA are lines that intersect in the first quad-
rant, thus the system has a unique positive fixed point. Let f(·) = ddt [LTRI ]
and g(·) = ddt [LTRA]. Observe that
∂f
∂(LTRI)
+
∂g
∂(LTRA)
= −(kA + kOFF + kON )− kI < 0. (14)
By Bendixson-Dulac criterion, the system does not have a periodic orbit.
Therefore the unique positive steady state is globally asymptotically stable, by
Poincare´ - Bendixson theorem. Furthermore, the unique positive steady state
of the LTR system takes the forms
LTR∗I =
kONkI
(kOFF + kON )kI + kONkA
(15)
LTR∗A =
kONkA
(kOFF + kON )kI + kONkA
(16)
LTR∗R = 1− LTR∗I − LTR∗A (17)
Stability of the original system follows by simply substituting equilibrium
values of LTRs into the rest of the equations. For instance, consider the rate
equation for TAR. Let NLTR denote αm1,RLTR
∗
R+αm1,ILTR
∗
I+αm1,ALTR
∗
A.
Then in the limit as t→∞, the rate of change of TAR becomes:
d
dt
(TAR) = NLTR − γm1TAR (18)
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This implies the unique positive steady state TAR∗ = NLTR/γm1 is glob-
ally stable. Similar argument holds for the remaining variables. Note that the
steady state of envA takes the form of a step function
env∗A =

αm2,ALTR
∗
A
va(γm2+αp2 )
if Tat∗ < Tatcrit
αm2,ALTR
∗
A
γm2+αp2
if Tat∗ ≥ Tatcrit
, (19)
where Tat∗ = (αp1env
∗
I)/γp1 .
The existence of the globally asymptotically stable positive steady state of
the system implies that the amount of virus would increase to a stable level
once the activation of HIV-1 takes place. However, such biological limit is
difficult to meaningfully incorporate into any modeling schemes. Thus, this
result should be interpreted as a stable increase in the amount of virus after
the activation of HIV-1. In Appendix 7.5 we derive the complete closed form
explicit steady state solution. In the case of this linear system we are able to
describe dependence of the steady state on each of the parameters; however,
a detailed examination of the sensitivity to each of the parameters is outside
of the scope of this work. An advantage of having an explicit solution is the
ability to estimate the rate of decay for each of the system variables using
corresponding eigenvalues of the Jacobi matrix. This could prove useful for
further analysis of the system and its potential modifications.
3.2 Stability in case of kA and fm continuously depending on Tat
The model described above contains discontinuities due to the switching of the
fm regimes based on Tat level, which may not be biologically valid. Further-
more, the switching function limits the ability of the model to distinguish the
transcriptional dynamics as Tat approaches the critical threshold Tatcrit for
T-cells and macrophages. In what follows, we introduce a continuous version
of the existing model by modifying the switches to the following form of Hill
function:
fm2(Tat) =
αm2,A
va
1 + va(Tat/Tc)
n
1 + (Tat/Tc)n
, va > 1 (20)
kA(Tat) =
βm2,A
vb
1 + vb(Tat/Tc)
m
1 + (Tat/Tc)m
, vb > 1 (21)
Here Tc denotes Tatcrit. Figure 2 shows that fm converges to the Heaviside
step function as n increases, asymptotycally approaching the form consid-
ered in the previous section, to characterize the Tat-dependent rates in the
transcription process. Not to impose additional assumptions, we reserve two
different Hill constants n and m for fm2(Tat) and kA(Tat). While n often takes
value between 2 and 3 in literature, or 1 in Chavali et al. (2015), the possible
biologically relevant ranges of n and m are all real numbers greater than or
equal to 1.
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Fig. 2 Hill function in Equation (20) for different values of n. A similar observation is seen
for the Hill function in Equation (21).
We start examining the properties of the modified system by looking at
its positive invariance. This is in line with our previous analysis since both
functional responses are positive and bounded.
Lemma 1 The system (1)-(9) under assumptions (20)-(21) is positively in-
variant.
Proof Since fm2(Tat) and kA(Tat) are bounded above by αm2,A and βm2,A
and va and vb are taken to be strictly greater than 1, the positive invariance of
the new system follows directly from the boundedness of the original system.
The introduction of the continuous functional responses allow for more in-
teresting coupling of the dynamics between different variables; however, the
overall dynamics of the system still does not rely on TAR, Pr55 and p24, since
they only feed on the other six variables. Additionally, within the remaining
six equations, envA does not contribute to the dynamics of the other five and
LTR is conserved. Thus, we start our analysis on the reduced system of four
differential equations (2),(3),(4),(6).
Define x = LTRI , y = LTRA, s = env I , v = Tat, a1 = kON , a2 = kI −
kON , a3 = kON + kOFF , a4 = kI , a5 = αp1 , a6 = γp1 , a7 = αm2,I , a8 = γm2 +
αp1 + αp2 , a9 = βm2,A/vb, a10 = vb/(Tc)
n and a11 = 1/(Tc)
n. Note that
a10 = vba11, so since we take vb to be strictly larger than 1, a10 > a11. In
these notations, the system takes on the form:
Title Suppressed Due to Excessive Length 11
x′ = a1 + (a4 − a1)y −
(
a3 + a9
1 + a10v
n
1 + a11vn
)
x (22)
y′ = a9
1 + a10v
n
1 + a11vn
x− a4y (23)
s′ = a7x− a8s (24)
v′ = a5s− a6v. (25)
As with the linear system, the nonlinear system also contains a zero steady
state that is always unstable whenever at least one of the initial conditions
for LTR is positive. Thus, we focus our analysis on the positive steady state.
Note that for n < 1, the Hill function exhibits dynamics that are unexpected
for our biological system, see Figure 2, so we discard that case.
Proposition 2 The reduced system, equation (22)-(25), has a unique positive
steady state for all n ≥ 1.
Proof In order to show the system has a unique positive steady state, we
proceed by finding the nullclines. Setting v′ = 0 and s′ = 0, we obtain:
x∗ =
a8
a7
s∗ (26)
s∗ =
a6
a5
v∗. (27)
Together, this gives:
v∗ =
a5a7
a6a8
x∗ =: w¯x∗, (28)
where w¯ = a5a7a6a8 . Next we set y
′ = 0 and solve for y∗ in term of x∗ to obtain:
y∗ =
a9
a4
1 + a10(v
∗)n
1 + a11(v∗)n
x∗ (29)
=
a9
a4
1 + a10(w¯x
∗)n
1 + a11(w¯x∗)n
x∗. (30)
Finally, setting x′ = 0 and replace in y∗.
a1 +
a9
a4
(a4 − a1)1 + a10(w¯x
∗)n
1 + a11(w¯x∗)n
x∗
−
(
a3 + a9
1 + a10(w¯x
∗)n
1 + a11(w¯x∗)n
)
x∗ = 0. (31)
Rearranging terms, we obtain:
a1 − a3x∗ = a1a9
a4
(
1 + a10(w¯x
∗)n
1 + a11(w¯x∗)n
)
x∗. (32)
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Letting g(x∗) := a1−a3x∗ and f(x∗) := a1a9a4
(
1+a10(w¯x
∗)n
1+a11(w¯x∗)n
)
x∗. Note that both
f(x∗) and g(x∗) are continuous and strictly monotone functions on x∗ ∈ [0, 1].
Furthermore, f(0) = 0 and f(1) > 0, while g(0) > 0 and g(1) = a1 − a3 =
−kOFF < 0. Thus invoking the intermediate value theorem, we have f(x∗)
and g(x∗) intersect at a unique point x∗ ∈ (0, 1). It follows immediately the
system has a unique positive equilibrium (x∗, y∗, s∗, v∗).
The positivity of the unique nontrivial steady state of our system helps
establish its biological validity. However, it does not rule out the possibility
of finding a steady state arbitrarily close to 0, which is unrealistic in practice
when HIV-1 viral load stays low but away from 0. For this reason, we establish
a proposition that establishes lower bounds on all system variables.
Recall that we say the system described in Equations (22-25) is permanent
if there are positive constant M and N such that
lim sup
t→∞
max{x(t), y(t), s(t), v(t)} < M, (33)
and if
lim inf
t→∞ min{x(t), y(t), s(t), v(t)} > N. (34)
We will show that the system in Equations (22-25) is permanent in the
above sense for n ≥ 1. By construction, x and y are bounded above by 1, so
we only need to show they also have a positive lower bound.
Proposition 3 There exist positive constants mx and my such that 0 < mx ≤
lim inft→∞ x and 0 < my ≤ lim inft→∞ y.
Proof First we note that all variables in Equations (22-25) are non-negative.
Thus, for all non-negative values of x, y, v, we consider a new variable X(t)
such that X(0) = x(0) and
X′ = min {a1, a4} − (a3 + a9vb) X. (35)
Consider x′ = a1 + (a4 − a1)y −
(
a3 + a9
1+a10v
n
1+a11vn
)
x. Observe that if a4 >
a1, then min{a1 + (a4 − a1)y} ≥ a1, with minimum achieved when y = 0.
Otherwise, a4 < a1, then min{a1 + (a4 − a1)y} ≥ a4 with minimum achieved
when y = 1. Furthermore, observe that
a3 + a9
1 + a10v
n
1 + a11vn
≤ a3 + a9 max
{
a10
a11
, 1
}
(36)
= a3 + a9 max{vb, 1} (37)
= a3 + a9vb, (38)
where the last equality follows from the assumption that the amplification
effect due to activation, vb, is strictly greater than 1.
Now, we claim that x(t) ≥ X(t) for all t ≥ 0. If not, then since x(t) and
X(t) are non-negative, x(0) = X(0) and x′(0) ≥ X′(0), there exists t1 > 0
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such that x(t) ≥ X(t) for t ∈ [0, t1) and x(t1) = X(t1) with x′(t1) < X′(t1).
However, we note that
x′(t1) = a1 + (a4 − a1)y(t1)−
(
a3 + a9
1 + a10v
n(t1)
1 + a11vn(t1)
)
x(t1) (39)
≥ min {a1, a4} − (a3 + a9vb)x(t1) (40)
= min {a1, a4} − (a3 + a9vb) X(t1) (41)
= X′(t1), (42)
which is a contradiction. Hence, x(t) ≥ X(t) for all t ≥ 0. Observe that since
limt→∞X(t) =
min{a1,a4}
a3+a9vb
, this implies
lim inf
t→∞ x(t) ≥ limt→∞X(t) =
min{a1, a4}
a3 + a9 max{a10, 1} > 0. (43)
Define mx =
min{a1,a4}
a3+a9vb
, then eventually x(t) ≥ mx > 0.
Consider Y(t) such that Y(0) = y(0) and
Y′ = a9mx − a4Y. (44)
Similarly, we obtain that y(t) ≥ Y(t) for t ≥ 0 and
lim inf
t→∞ y(t) ≥ limt→∞Y(t) =
a9mx
a4
> 0. (45)
Define my =
a9mx
a4
. This concludes our proof.
From Proposition 3, it is straightforward to show that s and v also have positive
lower and upper bound. Thus we state the following Lemma without proof.
Lemma 2 The system in Equations (22-25) is permanent.
Note that Lemma 2 also guarantees that the nonlinear system with kA(Tat)
and fm(Tat) continuously dependent on Tat is also permanent.
3.3 Two alternative 3-dimensional approximations
Even with the reduction, the asymptotic dynamics of the reduced system (22)-
(25) is still difficult to study. Thus, we examine two alternative models that
capture the asymptotic behavior of the reduced system.
First, since we often observe that αm2,I  γm2 + αp1 + αp2 (see Table 2),
it implies a7  a8. Thus, one may consider the quasi-steady state (QSS)
approximation that s(t) ≈ a7a8x(t) or env I ≈ a7a8 LTRI .
This gives the following QSS system:
x′ = a1 + (a4 − a1)y −
(
a3 + a9
1 + a10v
n
1 + a11vn
)
x (46)
y′ = a9
1 + a10v
n
1 + a11vn
x− a4y (47)
v′ = a5
a7
a8
x− a6v. (48)
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Alternatively, one can treat the s compartment as a delay factor in the
link between x and v. In other words, we assume s(t) ≈ a7a8x(t − τ), where τ
is a pre-determined time delay (τ ≈ 1/a8). This leads to the following Delay
system:
x′ = a1 + (a4 − a1)y −
(
a3 + a9
1 + a10v
n
1 + a11vn
)
x (49)
y′ = a9
1 + a10v
n
1 + a11vn
x− a4y (50)
v′ = a5
a7
a8
x(t− τ)− a6v. (51)
In Figure 3 we provide computational comparison of these two models against
the original one. Both approximations are able to capture asymptotic behavior
of the system, but there are noticeable differences in transient dynamics, as
expected.
Fig. 3 Numerical comparison between the 4-dimensional model (22)-(25), QSS model (46)-
(48) and Delayed model (49)-(51). The y-axis represents the arbitrary unit of the variable.
Parameter values are for T-cells. While all models show similar behavior for x and y dy-
namics, reduced models underestimate the growth of v variable and there are differences in
transient behavior for the s variable.
Since the Delayed model does not offer significant advantages over the
QSS model in terms of capturing long term system behavior based on this
calculation, in our stability analysis we will focus on the QSS model. We note
that the Delayed model might be useful in case a more careful analysis of the
transient mode is of interest.
3.4 Stability of the QSS model
For the quasi-steady state model (46)-(48), its boundedness, positive invari-
ance and the existence of a unique positive steady state are direct consequences
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of the results we established earlier for the original 4-dimensional model. Thus,
we only need show local asymptotic stability for the positive steady state.
Proposition 4 The positive steady state of the QSS system (46)-(48) is locally
asymptotically stable.
Proof We consider the Jacobian of the system at (x∗, y∗, v∗),
J(x∗, y∗, v∗) =
−
(
a3 + a9
1+a10(v
∗)n
1+a11(v∗)n
)
a4 − a1 −a9x∗ (a10−a11)n(v
∗)n−1
(1+a11(v∗)n)2
a9
1+a10(v
∗)n
1+a11(v∗)n
−a4 a9x∗ (a10−a11)n(v
∗)n−1
(1+a11(v∗)n)2
a5
a7
a8
0 −a6
 .(52)
Denote ∆1 := a9
1+a10(v
∗)n
1+a11(v∗)n
, ∆2 = a9x
∗ (a10−a11)n(v∗)n−1
(1+a11(v∗)n)2
and α = a5
a7
a8
. Then
the Jacobian matrix becomes:
J(x∗, y∗, v∗) =
− (a3 +∆1) a4 − a1 −∆2∆1 −a4 ∆2
α 0 −a6
 . (53)
Solving for the determinant of J(x∗, y∗, v∗) − Iλ to obtain the characteristic
equation,
det(J(x∗, y∗, v∗)− Iλ) =
− (a3 +∆1)− λ a4 − a1 −∆2∆1 −a4 − λ ∆2
α 0 −a6 − λ
 (54)
= −(a6 + λ)[(a4 + λ)(a3 +∆1 + λ)
−∆1(a4 − a1)]
+α[∆2(a4 − a1)−∆2(a4 + λ)] (55)
= −(a3a4a6 +∆1a1a6 + αa1∆2)
−λ(a4a6 + a3(a4 + a6)
+∆1(a6 + a1) + α∆2)
−λ2(a4 + a6 + a3 +∆1)− λ3. (56)
Thus the characteristic equation takes the form,
q(λ) = λ3 + λ2(a4 + a6 + a3 +∆1) + λ(a4a6 + a3(a4 + a6) +
+∆1(a6 + a1) + α∆2) + (a3a4a6 +∆1a1a6 + αa1∆2) (57)
=: λ3 + λ2A2 + λA1 +A0. (58)
Here A0 = a3a4a6 +∆1a1a6 +αa1∆2, A1 = a4a6 +a3(a4 +a6)+∆1(a6 +a1)+
α∆2 and A2 = a4 + a6 + a3 +∆1. By Routh-Hurwitz criterion, the condition
for stability is satisfied if: (1) A2, A0 > 0, and (2) A2 ·A1 > A0.
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Since all parameters are positive, the condition (1) is satisfied. Additionally,
A2 ·A1 −A0 = (a4 + a6 + a3 +∆1)
×(a4a6 + a3a4 + a3a6 + a6∆1 + a1∆1 + α∆2)
−(a3a4a6 + a1a6∆1 + αa1∆2) (59)
= (a4 + a6 + a3 +∆1)(a3a4 + a1∆1 + α∆2)
+(a4 + a6 + a3 +∆1)(a4a6 + a3a6 + a6a1)
−(a3a4a6 + a1a6∆1 + αa1∆2) (60)
= (a4 + a3 +∆1)(a3a4 + a1∆1 + α∆2)
+(a3 − a1)α∆2 + (a4 + a6 +∆1)α∆2
+(a4 + a6 + a3 +∆1)(a4a6 + a3a6 + a6a1). (61)
Since a3 = a1 + (a positive number) by definition, A2A1 > A0. Hence, the
second condition is also satisfied.
The complete global stability result is difficult to obtain even for the quasi-
steady state system (using standard Lyapunov functions). Instead, we observe
that Tatcrit is several orders of magnitude smaller than the value of Tat shortly
after the experiment starts. This means the nonlinear model is quickly reduced
to the linear model, unless Tatcrit is significantly larger. Qualitatively, this
means that if the production rate of Tat is high enough, then we can expect
the new model to show similar dynamical behavior to the original system
(e.g. the positive steady state is globally asymptotically stable). A similar
observation should hold for very low production rate of Tat.
In Fig. 4 we numerically study the dependence of steady state on varying
parameters over a reasonable range. The following results are representative
of the study. They show that under reasonable parameter ranges, the positive
steady state is always stable. These observations suggest that the unique fixed
point is expected to be global stable for the nonlinear system.
4 Parameter estimation - comparison of linear and nonlinear
models
In DeMarino et al. (2020), we collected time series data for TAR and total env
RNA. In that work, standard least squares method was used to fit the linear
model given by (1)-(9) under assumptions (10)-(11) to all the data points
simultaneously. We utilize the same method for direct comparison with the
behavior of the nonlinear model specified by (1)-(9) under assumptions (20)-
(21). The fitting parameters are given by αm1,A, αm2,A, γm1 and γm2 . While
it is also possible to fit other parameters (especially the degradation of Tat),
this objective will likely result in over-fitting due to limited data. Our main
purpose is to compare the values of numerically estimated parameters between
linear and nonlinear models.
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Fig. 4 Numerical results for estimating the effect of varying parameter n on the behavior
of the QSS system (46)-(48). Note that the positive steady state for x is very small, but
positive.
The function fmincon in MATLAB is used to estimate these parameters
within the same ranges as described in DeMarino et al. (2020). Additionally,
the range for vb is taken to be [1, 200] (i.e. around the value of va) and the
ranges for n and m are taken to be [1,∞) since there are no known biologi-
cal constraints for their upper bound. The estimated values are presented in
Table 2.
Fig. 5 Comparison of linear and nonlinear models fitted to env data in both T-cells and
macrophages. (a) env data and the fitted models behavior in macrophages. (b) env data
and the fitted models behavior in T-cells.
Figures 5-6 show that both models produce similar fits for both types of
cells. Dynamics for other variables are also very similar. This is likely because
even though the effect of Tat is significant in the dynamics of the model,
the values of Tat in the linear and non-linear model remain relatively similar
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Fig. 6 Comparison of linear and nonlinear models fitted to TAR data in both T-cells and
macrophages. (a) TAR data and the fitted models behavior in macrophages. (b) TAR data
and the fitted models behavior in T-cells.
Fig. 7 Comparison of the dynamics of Tat resulted from fitting the linear and nonlinear
models TAR data and env data in both T-cells and macrophages. (a) Tat dynamics in
macrophages. (b) Tat dynamics in T-cells.
before and immediately after reaching the Tatcrit threshold, see Figure 7(a).
Alternatively, it is also possible that the parameter Tatcrit is orders of mag-
nitude smaller than the value of Tat after several hours, see Figure 7(b). In
both scenarios, the effect of Tat on the dynamics of the system quickly satu-
rates in a similar manner in both models. However, the nonlinear model gives
a noticeable difference in the Tat dynamics as compared to the linear model
in the case of macrophages. Yet, both models produce similar dynamics for
Tat in T-cells. This observation poses an interesting modeling question (out-
side of the scope of this paper) that may also be biologically relevant: why
are the Tat dynamics predicted by both models only differ only in the case of
macrophages?
Title Suppressed Due to Excessive Length 19
Unit definition T-Cell macrophages
βm2,A [change/mL/hr] LTRI → LTRA same as kA(Tat) same as kA(Tat)
αm1,A [copies/mL/hr] LTRA → TAR 1.38× 107 5.25× 105
αm2,A [copies/mL/hr] LTRA → envI 2.47× 106 5.45× 104
γm,1 [TAR/mL/hr] TAR degradation 1.17× 104 2.68× 104
γm,2 [envI/mL/hr] envI degradation 2.25× 103 2.91× 104
vb unitless folds of increasing 10 10
n unitless degree of non-linearity 6.23 1
m unitless degree of non-linearity 4.98× 101 1
Table 2 Values of additional parameters for the nonlinear model. Parameters not mentioned
here are taken to be the same as their values in Table 1.
5 Effect of different drug types
5.1 The effect of drug type F07#13 in combination with standard treatments
of HIV
Concerning the drug F07#13, when it is administered, the values of w1, w5
increase higher than 1. This leads to an increase in the steady states LTR∗I and
LTR∗R, while LTR
∗
A will decrease. Consequently, the value of env
∗
I will increase,
while env∗A will decrease. These effects eventually affect the production of
Pr 55. Since Pr 55 can be used as a tracker for viral proteins production, the
effect of F07#13 may potentially be studied by looking at how it affects the
dynamics of Pr 55.
First we will demonstrate that it is not trivial that treatment using F07#13
will reduce the production of Pr 55. Note that F07#13 reduces the activation
rate of LTR, so it negatively affects the proportion of LTRA and consequen-
tially the production of envA and the corresponding production of Pr 55 from
envA. However, this comes at a cost of increasing the proportion of LTRI ,
which increases the production of env I that also contributes to the produc-
tion of Pr 55 at an equal rate to that of envA. The contributions of env I and
envA are reflected in the final state Pr 55
∗ at an equal rate of αp2w2αp3 . In other
words, it is not obvious whether or not F07#13 effectively decreases Pr 55.
For instance, consider their ratio when w2 = w3 = w4 = 1 (only F07#13
is present) and Tat∗ ≥ Tatcrit:
env∗I
env∗A
= w1w5
αm2,I
αm2,A
γm2 + αp2
γm2 + αp1 + αp2
kI
kA
. (62)
This shows that F07#13 affects the relative concentration of env∗I and env
∗
A;
however, the actual amount of increasing/decreasing due to F07#13 is not
clear.
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For the reasons mentioned above we take a different approach. We let
w := 1w1w5 and rewrite Pr 55
∗ in term of w:
Pr 55∗(w) =
(
αp2
αp3
)[
kONkI
kI(kON + kOFF ) + kONkAw
]
× αm2,I
γm2 + αp1 + αp2
+
(
αp2
αp3
)[
kONkA
kI(kON + kOFF ) + kONkAw
]
αm2,A
γm2 + αp2
w (63)
=
(
αp2
αp3
)[
kON
kI(kON + kOFF ) + kONkAw
]
×
(
kIαm2,I
γm2 + αp1 + αp2
+
kAαm2,A
γm2 + αp2
w
)
. (64)
Taking derivative with respect to w,
d
dw
Pr 55∗(w) =
(
αp2
αp3
)[
− (kON )(kONkA)
(kI(kON + kOFF ) + kONkAw)2
]
×
(
kIαm2,I
γm2 + αp1 + αp2
+
kAαm2,A
γm2 + αp2
w
)
+
(
αp2
αp3
)[
kON
kI(kON + kOFF ) + kONkAw
]
kAαm2,A
γm2 + αp2
(65)
=
(
αp2
αp3
)[
kON
kI(kON + kOFF ) + kONkAw
](
kAαm2,A
γm2 + αp2
)
[
1− kONkA
kI(kON + kOFF ) + kONkAw
×
(
w +
αm2,I
αm2,A
γm2 + αp2
γm2 + αp1 + αp2
kI
kA
)]
.
(66)
Now at w = 1 (or with no F07#13 drug), then
d
dw
Pr 55∗(w = 1) =
(
αp2
αp3
)[
kON
kI(kON + kOFF ) + kONkA
](
kAαm2,A
γm2 + αp2
)
[
1− kONkA
kI(kON + kOFF ) + kONkA
(
1 +
αm2,I
αm2,A
γm2 + αp2
γm2 + αp1 + αp2
kI
kA
)]
(67)
=
(
αp2
αp3
)[
kON
kI(kON + kOFF ) + kONkA
](
kAαm2,A
γm2 + αp2
)
[
1− kONkA
kI(kON + kOFF ) + kONkA
(
1 +
env∗I
env∗A
)]
. (68)
Recall that w = 1w1w5 , so increasing w1w5 leads to decreasing w. Thus if
we want the drug F07#13 to decrease the amount of Pr 55, then we require
d
dw Pr 55
∗(w = 1) > 0. This leads to the condition
kONkA
kI(kON + kOFF ) + kONkA
(
1 +
αm2,I
αm2,A
γm2 + αp2
γm2 + αp1 + αp2
kI
kA
)
< 1 (69)
Title Suppressed Due to Excessive Length 21
If we expand the above inequality, we obtain:
αm2,I
αm2,A
γm2 + αp2
γm2 + αp1 + αp2
< 1 +
kOFF
kON
, (70)
or
αm2,I
αm2,A
<
(
1 +
kOFF
kON
)(
1 +
αp1
γm2 + αp2
)
. (71)
This means that for the drug F07#13 to be effective in reducing the equi-
librium value of Pr 55, the ratio between the rates of production αm2,I and
αm2,A must satisfy the condition in (71). Note that this condition is neces-
sary because even though F07#13 may appear to be effective initially, it may
not decrease the equilibrium value of Pr 55, see Figure 9.e in DeMarino et al.
(2020).
We remark that this result is only valid close to w = 1, so it may not
be applicable in general (e.g. wF07#13 ≈ 0.1 in T-cell). However, the idea
is the same in the general case, so for the drug to be effective, we require
d
dw Pr 55
∗(w) > 0 for 0 < w ≤ 1, or equivalently,[
1− kONkA
kI(kON + kOFF ) + kONkAw
(
w +
αm2,I
αm2,A
γm,2 + αp2
γm2 + αp1 + αp2
kI
kA
)]
> 0.
(72)
If this inequality holds, then we can expect the F07#13 to be effective in
decreasing Pr 55, which will subsequently decrease production of p24. Similar
analysis holds when Tat∗ < Tatcrit. Additionally, if all drugs are considered,
e.g. w2, w3, w4 > 1, then the condition becomes:
[
1− kONkAw
∗
kI(kON + kOFF ) + kONkAw∗w
(
w
w∗
+
αm2,I
αm2,A
γm,2 + αp2
γm2 + αp1 + αp2
kI
kA
)]
> 0
(73)
where w∗ := w3w4. This suggests the effect of the F07#13 drug can be en-
hanced by the other drugs. Equation (73) represents the generalization of (71),
accounting for other drugs and including all values of w ∈ (0, 1). Figure 8
demonstrates an example of the condition (71).
The maturation of Pr 55 to p24 is targeted by the standard HIV-1 treat-
ment cART (recall that this is represented by the parameter w2 in the model).
In Figure 9, we show the possible effects of combining F07#13 and cART.
Figure 9(a) shows that while both cART and F07#13 are effective in reducing
the amount of p24 at 200 hours, when they are used in combination, the level
of p24 is reduced further. Additionally, we provide a sample synergy map be-
tween F07#13 and cART (without accounting for toxicity) in Figure 9(b). In
that figure, an arbitrary p24 level (e.g. 1.2×106) is used to emphasize the syn-
ergistic effect between the two treatments. The light grey area represents p24
level above the threshold, while the dark grey area represents p24 level below
the threshold. Since the boundary leans toward a higher dosage of F07#13,
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Fig. 8 Using the parameters for the linear model for T-cells given in Table 1, we compare
the effect of F07#13 on the dynamics of Pr 55 for different levels of αp1 . (a) Without
modification to the parameter, the condition (71) is satisfieda and F07#13 is effective in
reducing the level of Pr 55. (b) By reducing the parameter αp1 1000 folds we break the
condition (71), leading to the ineffectiveness of F07#13 in reducing the level of Pr 55.
Fig. 9 Using the parameters for the linear model for T-cells given in Table 1, we compare the
effect of F07#13 and cART on the dynamics of p24. The effect of cART is set at 3 (w3 = 3),
meaning it reduces the production of p24 from Pr 55 to a third. (a) The combination of
F07#13 and cART reduces the level of p24 lower than either treatment alone. (b) Level of
p24 at 200 hours with varying amounts of F07#13 and cART. Both axes represent the fold
change in the drug level of F07#13 and cART. We use an arbitrary threshold 1.2× 106 to
emphasize the effect in varying F07#13 and cART with respect to one another. The light
grey area represents p24 level above the threshold, while the dark grey area represents p24
level below the threshold.
this shows that there is synergy between the two drugs. However, because we
do not consider the toxicity level and there is some lack of confidence in the ex-
act values of the drug effect/amount, further study with more comprehensive
data is required to estimate the specific value of the synergy between F07#13
and cART.
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6 Discussion
HIV-1 continues to be a serious problem worldwide. Despite tremendous ef-
forts, the ultimate cure for HIV-1 is yet to be discovered. Standard treatments,
such as cART, target multiple key points in the production of HIV; however,
a low level of viral products persists during latency partially due to the lack of
an FDA-approved drug to inhibit the viral transcription process. This chronic
state of HIV-1 is often accompanied by neurocognitive disorders in many pa-
tients using cART (Heaton et al., 2010; Mothobi and Brew, 2012). Addition-
ally, experimental drugs often fail during the phase of clinical trials (Khanna,
2012; Hwang et al., 2016). This is partially due to a lack of quantitative meth-
ods to predict the drug’s efficacy and toxicity especially in combination with
other drugs. Thus, a basic understanding of these mechanisms for HIV-1 is
crucial for the successful development of new therapies.
In this work, we carry out systematic analyses of the properties of a model
of the HIV-1 transcription process that incorporates three distinct promoter
states (repressed, intermediate, and activated), introduced in DeMarino et al.
(2020). To address the discontinuity in the functional response chosen in the
original model formulation, we introduce a nonlinear version of the model.
The comparison of the two versions of the model reveals interesting biological
insights into the transcription process for HIV-1. Finally, a theoretical study
of the effectiveness of the experimentally-driven drug F07#13 is carried out.
We summarize and further discuss our findings below.
The linear model of (DeMarino et al., 2020) satisfies basic bi-
ological properties. For the original system, we show that it is positively
invariant given at least one of the LTR states is initially positive. Additionally,
we show that all solutions tend to a positive steady state, which is explicitly
provided. The stability of the steady is difficult to link to a biological limit
(e.g. resource limitation, etc.). Instead, we should interpret this result as a sta-
ble increase in the viral HIV-1 load once the activation of transcription starts.
Furthermore, the availability of the closed form solution allows for direct quan-
tification of the expected viral level and its exponential transcriptional rates,
allowing to assess their effect on the transcription process.
Stability results for the extended system. To address the discon-
tinuity in the original formulation, we use a continuous functional response
that represents the Tat-dependent activation rate. We then carry out system-
atic analyses on the new model. We compare the fitting of the new model to
the original version given in DeMarino et al. (2020) to validate its capability
to capture the transcriptional dynamics of HIV-1, as shown in Figures 5-6.
Furthermore, to show the full capability of the extended model to capture
the dynamics of the process, we carry out numerical fitting in Figures 10-11.
The extended system shares many similarities with the original system. For
instance, all solutions are positive, bounded and permanent given reasonable
initial conditions. It also exhibits a unique positive steady state; however,
the stability analysis of this steady state is non-trivial due to the nonlinear
functional form of Tat-dependent activation. By making some simplifying as-
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sumptions, we show that the positive steady state is locally asymptotically
stable in the special case. Furthermore, we see that the extended system can
be simplified to the original system in the limit when the production of Tat
is either very high or very low. Thus, we conjecture that the positive steady
state is globally stable in the general case.
The estimated values of the nonlinear parameters (vb, n,m) sug-
gest distinctive differences between T-cells and macrophages. Recall
that the larger the values of n and m are, the more alike to a switching func-
tion ka(Tat) and fm(Tat) become, see Figure 2. In T-cells, the large values of
n and m (6.23 and 49.8, respectively) suggest more abrupt changes in the level
of transcriptional dynamics as Tat approaches the critical threshold Tatcrit,
see Table 2. On the other hand, the small value of n and m (both are 1)
in macrophages suggest a smoother transition. Additionally, the fold change
kA(Tat), vb, is significantly lower than fm(Tat), va, which suggests the increase
in promoter activation level before and after Tat reaches Tatcrit is significantly
lower than that of the production of envA over the same transition. Note that
these observations still hold even when parameter uncertainty is taken into
account, see Table 3.
The transcriptional inhibitor F07#13 is effective in reducing viral
production. Furthermore, it is synergetic to standard treatments. A
useful application of mathematical models is to test the effectiveness of pre-
clinical drugs in silico. To this end, we study the effect of the HIV-1 tran-
scription inhibitor drug F07#13. The previous simulation in Figure 9(e) in
DeMarino et al. (2020) shows that while a drug (e.g. F07#13) may appear
to be ineffective (or effective) initially, the end-result may differ. This leads
to us establishing a condition that ensures the end-effectiveness of F07#13
– that can be applied similarly to other drugs. Furthermore, we generalize
this condition to include the effect of other drugs, which can allow a study of
combination therapy to be carried out naturally. Our simulation and analyses
suggest that the incorporation of HIV-1 transcription inhibitors, such as F07,
in combination with other HIV-1 treatments may improve their efficacy due
to their synergy with one another, see Figure 9.
Using a combination of mathematical analysis and computational simu-
lations, we show interesting observations in the transcriptional dynamics of
HIV-1, especially the differentiation in behaviors in the case of T-cells and
macrophages. While our model is constructed based on current biological
knowledge and validated with experimental data, it is not without limita-
tions. The model is constructed for the analysis of short term transcriptional
dynamics of HIV-1 (on the order of days). Thus, many of the rate parameters
are linear, making it unsuitable to study the long term dynamics of HIV-
1 (over months or years). Additionally, the model does not account for the
difference between degradation and exit rates of certain variables. While the
model can be modified to account for the extracellular contents to distinguish
between degradation and exit rates, this would further increase the complex-
ity of the model. Furthermore, we hypothesized the functional forms of the
Tat-dependent activation, which may perhaps be improved upon in future at-
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tempts. Finally, while we provide the condition for drug effectiveness in the
case of the original model, toxicity may also be included in the case of the
nonlinear model to provide stronger insights. On the analytical side, while we
were able to establish basic properties for the linear and nonlinear models in
this work, the global stability analysis is still an open question. However, our
simulation strongly suggests the existence of a unique globally asymptotically
stable positive steady state for the nonlinear model. With regards to numeri-
cal aspects, we carry out basic data fitting and simulations to show differences
in dynamical behavior between T-cells and macrophages. Perhaps extensive
sensitivity analysis can be carried out to aid with the fitting process in the
future. Additional data would also allow for better uncertainty quantification
for the estimated parameter values and model predictions. Finally, while we
consider the primary effect of the transcriptional inhibitor F07#13 to reduce
the activation rate of LTR, other secondary effects of F07#13 are not taken
into account. Thus, a direct extension would be to account for all known ef-
fects of F07#13 and cART (along with their potential toxicity) in the study of
treatment combination. Such a study may prove useful in drug development
for clinical application.
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7 Appendix
7.1 Basic properties of the linear model
Note that in the original model, all negative terms in each variable’s rate equa-
tion is proportional to the variable itself. This implies if the model starts out
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with positive initial conditions, it will never become negative. The subsystem
LTRR,LTRI ,LTRA is conserved, so the zero steady state is always unstable
given at least one of the LTR state is positive initially. Furthermore, since
the system (equation 1-9) has a globally stable unique positive steady state
(see Theorem 1), the system is bounded eventually. Thus we arrive at the
proposition.
Proposition 5 The system in Equation 1-9 is positively invariant and even-
tually bounded.
7.2 Calculation of steady states for the case of constant rate between the
intermediate to activated LTR and piecewise production of activated
envelope
In dimension-reduced form (using 1 = LTRR + LTRI + LTRA), the rate of
change of LTRI becomes:
d
dt
[LTRI ] = kON −
(
w3w4
w5
kA + kOFF + kON
)
LTRI
+(w1kI − kON )LTRA (74)
Setting LTR′A = 0 and solve for LTR
∗
I in term of LTR
∗
A gives:
LTR∗I =
w1w5
w3w4
kI
kA
LTR∗A (75)
Replacing LTR∗I into LTR
′
I = 0 to solve for LTR
∗
A:
LTR∗A =
w3w4
w1w5
kONkA
kI(kON + kOFF ) + kONkA
(
w3w4
w1w5
) (76)
Using the relation between LTR∗I and LTR
∗
A, we obtain:
LTR∗I =
w1w5
w3w4
kI
kA
LTR∗A (77)
=
kONkI
kI(kON + kOFF ) + kONkA
(
w3w4
w1w5
) (78)
And similarly for LTR∗R:
LTR∗R =
kOFF
kON
LTR∗I (79)
=
kOFF kI
kI(kON + kOFF ) + kONKA
(
w3w4
w1w5
) (80)
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We proceed to compute the steady states of the remaining variables. In the
asymptotic limit, then env ′I becomes
env ′I = αm2,ILTR
∗
I − (γm,2 + αp1 + αp,2)env I (81)
It follows that
env∗I =
αm2,ILTR
∗
I
γm,2 + αp1 + αp2
(82)
Similarly,
Tat∗ =
αp1env
∗
I
γp1
(83)
And
TAR∗ =
αm1,RLTR
∗
A + αm1,ILTR
∗
I + αm1,ALTRA
γm1
(84)
Then,
env∗A =

αm2,ALTR
∗
A
va(γm2+αp2 )
if Tat∗ < Tatcrit
αm2,ALTR
∗
A
γm2+αp2
if Tat∗ ≥ Tatcrit
(85)
where Tat∗ = αp1env
∗
I
γp1
. Finally,
Pr55∗ =
αp2env
∗
I + αp2env
∗
A
αp3
(86)
and
p24∗ =
αp3
γp2
Pr55∗
w2
(87)
7.3 Confidence interval on parameter estimation
The function fmincon does not provide the Jacobian matrix needed to calcu-
late the confidence interval for parameter estimation. Instead, we utilize the
function lsqnonlin, a different MATLAB function for nonlinear fitting, to es-
tablish confidence on our parameter estimates. Due to the biologically realistic
constraints on some parameters in the optimization process, the confidence in-
tervals established here may not be reliable for certain parameters. However,
it still provides a good estimate of the uncertainty related to the model and
the available data. We note that the fitting results are comparable between
lsqnonlin and fmincon; however, we elect to use fmincon in the main draft to
be consistent with the original publication (DeMarino et al., 2020).
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T-Cell macrophages
αm1,A 1.70× 107[0, 4.4× 107] 4.56× 105[2.52× 105, 6.57× 105]
αm2,A 2.47× 106[0, 1.09× 107] 4.04× 104[0, 1.32× 105]
γm,1 2.63× 104[0, 8.41× 104] 2.68× 104[1.16× 104, 4.19× 106]
γm,2 2.00× 103[0, 8.08× 104] 5.91× 102[0, 5.31× 104]
αm1,A 1.30× 107[0, 1.24× 108] 5.28× 105[0, 2.12× 106]
αm2,A 1.75× 106[0, 2.03× 107] 5.32× 104[0, 5.03× 105]
γm,1 1.82× 104[0, 2.41× 105] 2.68× 104[0, 7.00× 104]
γm,2 1.10× 103[0, 1.88× 105] 5.91[0, 1.58× 105]
vb 1.47× 102[10, 1.31× 107] 10[10, 5.71× 102]
n 2.10[1, 2.05× 103] 1[1, 1.65× 101]
m 1.34× 102[1, 1.19× 108] 1[1, 2.28× 101]
Table 3 Confidence intervals of estimated parameters using lsqnonlin for the linear (top
half) and non-linear (bottom half) models. The estimated value is provided with the lower
and upper 95% confidence interval. Note that when the lower bound of the 95% confidence
interval is not biologically reasonable, we set it to the biological bound. The estimated values
of the parameters are similar to that of fmincon.
7.4 Fitting using all parameters
In Figures 5 and 6, we only attempt to fit four (linear model) and seven (non-
linear model) parameters. This reservation is due to the limited available data
and to avoid potential problem of identifiability. However, in this subsection,
we will demonstrate the flexibility of both models to capture the dynamics
of the HIV-1 transcription process by fitting to all parameters (with the ex-
ception of the drug-related parameters wi). The results are demonstrated in
Figures 10 and 11.
Fig. 10 Comparison of linear and nonlinear model for env-data fitting in both T-cells and
macrophages. (a) ENV data and fitting in macrophages. (b) ENV data and fitting in T-cells.
The fitting is carried out using all parameters.
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Fig. 11 Comparison of linear and nonlinear model for TAR-data fitting in both T-cells and
macrophages. (a) TAR data and fitting in macrophages. (b) TAR data and fitting in T-cells.
The fitting is carried out using all parameters.
7.5 Exact solution in the case of constant rates
The equations examined here correspond to the model defined in the main text
with all coefficients taken to be constant. To simplify notation we have not
included the drug treatment factors wi but those can be easily incorporated
by a re-interpretation of the coefficients.
d
dt
[LTRR] = −kONLTRR + kOFFLTRI (88)
d
dt
[LTRI ] = kONLTRR − [kA + kOFF ] LTRI + kILTRA (89)
d
dt
[LTRA] = kA LTRI − kILTRA (90)
d
dt
[TAR] = αm1,RLTRR + αm1,ILTRI + αm1,ALTRA − γm1TAR (91)
d
dt
[env I ] = αm2,ILTRI − (γm,2 + αp1 + αp2) env I (92)
d
dt
[envA] = αm2,ALTRA − (γm,2 + αp2) envA (93)
d
dt
[Tat] = αp1env I − γp1Tat (94)
dPr55
dt
= αp2env I + αp2envA − αp3Pr55 (95)
dP24
dt
= αp3Pr55 − γp2P24 (96)
Note that in the Tat equation we have used a constant coefficient αm2,A
as the multiplier on the LTRA term. In our full model we also examined
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the piecewise-constant case where αm2,A/va if Tat < Tatcrit and αm2,A if
Tat ≥ Tatcrit. The solutions presented below can be adapted to address this
piecewise-constant situation by reusing the formulas starting at a new time
t = t0 and with new initial conditions LTRR(t = t
0) := LTR0R, LTR(t = t
0) :=
LTR0I , etc. along with a numerical calculation of t
0 = tcrit as the time for which
Tat reaches Tatcrit. We have validated this approach by comparing the exact
solution with piecewise-constants with numerically-computed solutions using
MATLAB’s ode solver ode23s.
LTR equations Suppose kOFF , kON , kA and kI are constant. The LTR
equations decouple from the rest and can be solved first.
d
dt
[LTRR] = −kONLTRR + kOFFLTRI (97)
d
dt
[LTRI ] = kONLTRR − [kA + kOFF ] LTRI + kILTRA (98)
d
dt
[LTRA] = kA LTRI − kILTRA. (99)
This is a solvable linear system that can be expressed in matrix form
dL
dt
=
−a b 0a −b− c d
0 c −d
L ≡ A L, (100)
where
L =
LTRRLTRI
LTRA
 , (101)
and for convenience we introduce matrix entries
a = kON , b = kOFF , c = kA, d = kI . (102)
Solutions to equation (100) have the form veλt with eigenvector v and
eigenvalue λ satisfying Av = λv. In particular, the eigenvalues of A satisfy
0 = λ
[
λ2 + (a+ b+ c+ d)λ+ (ac+ ad+ bd)
]
. (103)
So λ = λ0 = 0, λ = λ1 and λ = λ2 where
λ1,2 =
1
2
[
−(a+ b+ c+ d)±
√
(a+ b+ c+ d)2 − 4(ac+ ad+ bd)
]
(104)
The eigenvectors corresponding to λ0, λ1, and λ2 are
vi =
 b(d+ λi)(a+ λi)(d+ λi)
c(a+ λi)
 for i = 0, 1, 2. (105)
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Then,
L =
LTRR(t)LTRI(t)
LTRA(t)
 = 2∑
i=0
civie
λi(t−t0), (106)
where the constants ci for i = 0, 1, 2 are solutions of the linear system bd b(d+ λ1) b(d+ λ2)ad (a+ λ1)(d+ λ1) (a+ λ2)(d+ λ2)
ca c(a+ λ1) c(a+ λ2)
 c0c1
c2
 =
LTR0RLTR0I
LTR0A
 , (107)
and LTR0R, LTR
0
I , and LTR
0
A are the three LTR values at t = t
0 (Note that t0
could be zero or some other suitable time). Once the values of c0, c1, and c2
are determined then equation (106) represents the LTR solution for the case
of constant kON , kOFF , kA, and kI .
RNA equations - TAR, env I , envA
The equations for the short and long RNA sequences are
d
dt
[TAR] = αm1,RLTRR + αm1,ILTRI + αm1,ALTRA − γm1TAR (108)
d
dt
[env I ] = αm2,ILTRI − (γm,2 + αp1 + αp2) env I (109)
d
dt
[envA] = αm2,ALTRA − (γm,2 + αp2) envA (110)
Note that since LTRR, LTRI , and LTRA are linear combinations of expo-
nential functions (or a constant) all three of these equations have the general
form
dy
dt
+ γy = p0 +
2∑
i=1
pie
λi(t−t0). (111)
Introducing an integrating factor eγ(t−t
0), integrating, and using y(t0) = y0
leads to the solution
y = y0e−γ(t−t
0) +
p0
γ
(
1− e−γ(t−t0)
)
+
2∑
i=1
pi
λi + γ
(
eλi(t−t
0) − e−γ(t−t0)
)
, if γ 6= 0, (112)
y = y0 + p0(t− t0) +
2∑
i=1
pi
λi
(
eλi(t−t
0) − 1
)
, if γ = 0. (113)
In the following three subsections we write out the values for γ, p0, p1, and
p2 for the TAR, env I , and envA equations.
TAR equation
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d
dt
[TAR] + γm1TAR = αm1,RLTRR + αm1,ILTRI + αm1,ALTRA
= αm1,R
(
c0bd+ c1b(d+ λ1)e
λ1(t−t0) + c2b(d+ λ2)eλ2(t−t
0)
)
+ αm1,I
(
c0ad+ c1(a+ λ1)(d+ λ1)e
λ1(t−t0) + c2(a+ λ2)(d+ λ2)eλ2(t−t
0)
)
,
+ αm1,A
(
c0ca+ c1c(a+ λ1)e
λ1(t−t0) + c2c(a+ λ2)eλ2(t−t
0)
)
(114)
so for this case
γ = γm1 ≡ γ(TAR), (115)
p0 = c0 (αm1,Rbd+ αm1,Iad+ αm1,Aac) ≡ p(TAR)0 , (116)
p1 = c1 (αm1,Rb(d+ λ1) + αm1,I(a+ λ1)(d+ λ1) + αm1,Ac(a+ λ1))
≡ p(TAR)1 , (117)
p2 = c2 (αm1,Rb(d+ λ2) + αm1,I(a+ λ2)(d+ λ2) + αm1,Ac(a+ λ2))
≡ p(TAR)2 . (118)
Then,
TAR = TAR0e−γ(t−t
0) +
p0
γ
(
1− e−γ(t−t0)
)
+
2∑
i=1
pi
λi + γ
(
eλi(t−t
0) − e−γ(t−t0)
)
, if γ 6= 0, (119)
TAR = TAR0 + p0(t− t0) +
2∑
i=1
pi
λi
(
eλi(t−t
0) − 1
)
, if γ = 0. (120)
env I equation
d
dt
[env I ] + (γm,2 + αp1 + αp2) env I = αm2,ILTRI
= αm2,I
(
c0ad+ c1(a+ λ1)(d+ λ1)e
λ1(t−t0)
+c2(a+ λ2)(d+ λ2)e
λ2(t−t0)
)
, (121)
so for this case
γ = γm,2 + αp1 + αp2 ≡ γ(I), (122)
p0 = αm2,Ic0ad ≡ p(I)0 , (123)
p1 = αm2,Ic1(a+ λ1)(d+ λ1) ≡ p(I)1 , (124)
p2 = αm2,Ic2(a+ λ2)(d+ λ2) ≡ p(I)2 . (125)
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Then,
env I = env
0
Ie
−γ(t−t0) +
p0
γ
(
1− e−γ(t−t0)
)
+
2∑
i=1
pi
λi + γ
(
eλi(t−t
0) − e−γ(t−t0)
)
, if γ 6= 0, (126)
env I = env
0
I + p0(t− t0) +
2∑
i=1
pi
λi
(
eλi(t−t
0) − 1
)
, if γ = 0. (127)
envA equation
d
dt
[envA] + (γm,2 + αp2) envA = αm2,ALTRA (128)
= αm2,A
(
c0ca+ c1c(a+ λ1)e
λ1(t−t0) + c2c(a+ λ2)eλ2(t−t
0)
)
,
so for this case
γ = γm,2 + αp2 ≡ γ(A), (129)
p0 = αm2,Ac0ca ≡ p(A)0 , (130)
p1 = αm2,Ac1c(a+ λ1) ≡ p(A)1 , (131)
p2 = αm2,Ac2c(a+ λ2) ≡ p(A)2 . (132)
Then,
envA = env
0
Ae
−γ(t−t0) +
p0
γ
(
1− e−γ(t−t0)
)
+
2∑
i=1
pi
λi + γ
(
eλi(t−t
0) − e−γ(t−t0)
)
, if γ 6= 0, (133)
envA = env
0
A + p0(t− t0) +
2∑
i=1
pi
λi
(
eλi(t−t
0) − 1
)
, if γ = 0. (134)
Tat equation
d
dt
[Tat] + γp1Tat = αp1env I . (135)
In this subsection for Tat we have
y0 = env0I , (136)
γ = γm,2 + αp1 + αp2 = γ
(I), (137)
p0 = αm2,Ic0ad = p
(I)
0 , (138)
p1 = αm2,Ic1(a+ λ1)(d+ λ1) = p
(I)
1 , (139)
p2 = αm2,Ic2(a+ λ2)(d+ λ2) = p
(I)
2 . (140)
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case γ 6= 0, γp1 6= 0, γ 6= γp1
Based on the form of env I , and noting γ = γm,2 +αp1 +αp2 , this equation
has the form
dTat
dt
+ γp1Tat = αp1
[
y0e−γ(t−t
0) +
p0
γ
(
1− e−γ(t−t0)
)
+
2∑
i=1
pi
λi + γ
(
eλi(t−t
0) − e−γ(t−t0)
)]
,
= αp1
p0
γ
+ αp1
[
2∑
i=1
pi
λi + γ
eλi(t−t
0)
]
+ αp1
[
y0 − p0
γ
−
2∑
i=1
pi
λi + γ
]
e−γ(t−t
0),
= q0 +
2∑
i=1
qie
λi(t−t0) + q3e−γ(t−t
0). (141)
where
q0 = αp1
p0
γ
qi = αp1
pi
λi + γ
for i = 1, 2
q3 = αp1
[
y0 − p0
γ
−
2∑
i=1
pi
λi + γ
]
. (142)
In this case
Tat = Tat0e−γp1 (t−t
0) +
q0
γp1
[
1− e−γp1 (t−t0)
]
+
2∑
i=1
qi
λi + γp1
[
eλi(t−t
0) − e−γp1 (t−t0)
]
+
q3
γp1 − γ
[
e−γ(t−t
0) − e−γp1 (t−t0)
]
(143)
case γ 6= 0, γp1 = 0
Here the equation for Tat is
dTat
dt
= q0 +
2∑
i=1
qie
λi(t−t0) + q3e−γ(t−t
0), (144)
where
q0 = αp1
p0
γ
qi = αp1
pi
λi + γ
for i = 1, 2
q3 = αp1
[
y0 − p0
γ
−
2∑
i=1
pi
λi + γ
]
. (145)
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In this case
Tat = Tat0 + q0(t− t0) +
2∑
i=1
qi
λi
[
eλi(t−t
0) − 1
]
− q3
γ
[
e−γ(t−t
0) − 1
]
(146)
case γ = γp1 6= 0
Here the equation for Tat is
dTat
dt
+ γTat = q0 +
2∑
i=1
qie
λi(t−t0) + q3e−γ(t−t
0). (147)
where
q0 = αp1
p0
γ
qi = αp1
pi
λi + γ
for i = 1, 2
q3 = αp1
[
y0 − p0
γ
−
2∑
i=1
pi
λi + γ
]
. (148)
In this case
Tat = Tat0e−γ(t−t
0) +
q0
γ
[
1− e−γ(t−t0)
]
+
2∑
i=1
qi
λi + γ
[
eλi(t−t
0) − e−γ(t−t0)
]
+ q3(t− t0)e−γ(t−t0) (149)
case γ = 0, γp1 6= 0
Here the equation for Tat is
dTat
dt
+ γp1Tat = q0 +
2∑
i=1
qie
λi(t−t0) + q3(t− t0). (150)
where
q0 = αp1
[
y0 −
2∑
i=1
pi
λi
]
qi = αp1
pi
λi
for i = 1, 2
q3 = αp1p0. (151)
In this case
Tat = Tat0e−γp1 (t−t
0) +
q0
γp1
[
1− e−γp1 (t−t0)
]
+
2∑
i=1
qi
λi + γp1
[
eλi(t−t
0) − e−γp1 (t−t0)
]
+
q3
γ2p1
[
e−γp1 (t−t
0) − 1 + γp1(t− t0)
]
(152)
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case γ = γp1 = 0
Here the equation for Tat is
dTat
dt
= q0 +
2∑
i=1
qie
λi(t−t0) + q3(t− t0). (153)
where
q0 = αp1
[
y0 −
2∑
i=1
pi
λi
]
qi = αp1
pi
λi
for i = 1, 2
q3 = αp1p0. (154)
In this case
Tat = Tat0 + q0(t− t0) +
2∑
i=1
qi
λi
[
eλi(t−t
0) − 1
]
+
1
2
q3(t− t0)2 (155)
Pr55 equation
dPr55
dt
+ αp3Pr55 = αp2env I + αp2envA (156)
In this case αp3 6= 0 (we do not consider αp3 = 0). Also we’ll assume
γ(I) 6= 0 and γ(A) 6= 0.
Inserting the results for env I and envA and also introducing notation α
(I)
p2
and α
(A)
p2 for the two αp2 coefficients leads to
d
dt
[
eαp3 (t−t
0)Pr55
]
= α(I)p2 env
0
Ie
(αp3−γ(I))(t−t0) + α(I)p2
p
(I)
0
γ(I)
(
eαp3 (t−t
0) − e(αp3−γ(I))(t−t0)
)
+ α(I)p2
2∑
i=1
p
(I)
i
λi + γ(I)
(
e(αp3+λi)(t−t
0) − e(αp3−γ(I))(t−t0)
)
+ α(A)p2 env
0
Ae
(αp3−γ(A))(t−t0) + α(A)p2
p
(A)
0
γ(A)
(
eαp3 (t−t
0) − e(αp3−γ)(t−t0)
)
+ α(A)p2
2∑
i=1
p
(A)
i
λi + γ(A)
(
e(αp3+λi)(t−t
0) − e(αp3−γ(A))(t−t0)
)
(157)
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Integrating, using the condition Pr55(t
0) = P 0r55 gives
Pr55 = P
0
r55e
−αp3 (t−t0) +
α
(I)
p2 env
0
I
αp3 − γ(I)
[
e−γ
(I)(t−t0) − e−αp3 (t−t0)
]
+
α
(I)
p2 p
(I)
0
γ(I)
[
1
αp3
(
1− e−αp3 (t−t0)
)
− 1
αp3 − γ(I)
(
e−γ
(I)(t−t0) − e−αp3 (t−t0)
)]
+ α(I)p2
2∑
i=1
p
(I)
i
λi + γ(I)
[
eλi(t−t
0) − e−αp3 (t−t0)
αp3 + λi
− e
−γ(I)(t−t0) − e−αp3 (t−t0)
αp3 − γ(I)
]
+
α
(A)
p2 env
0
A
αp3 − γ(A)
[
e−γ
(A)(t−t0) − e−αp3 (t−t0)
]
+
α
(A)
p2 p
(A)
0
γ(A)
[
1
αp3
(
1− e−αp3 (t−t0)
)
− 1
αp3 − γ(A)
(
e−γ
(A)(t−t0) − e−αp3 (t−t0)
)]
+ α(A)p2
2∑
i=1
p
(A)
i
λi + γ(A)
[
eλi(t−t
0) − e−αp3 (t−t0)
αp3 + λi
− e
−γ(A)(t−t0) − e−αp3 (t−t0)
αp3 − γ(A)
]
.(158)
This expression has common exponential forms. Combining these gives
Pr55 = r0 + r1e
−αp3 (t−t0) + r(I)2 e
−γ(I)(t−t0) + r(A)2 e
−γ(A)(t−t0) +
2∑
i=1
r3ie
λi(t−t0),
(159)
where
r0 =
α
(I)
p2 p
(I)
0
αp3γ
(I)
+
α
(A)
p2 p
(A)
0
αp3γ
(A)
, (160)
r1 = P
0
r55 −
α
(I)
p2 env
0
I
αp3 − γ(I)
− α
(I)
p2 p
(I)
0
αp3γ
(I)
+
α
(I)
p2 p
(I)
0
γ(I)
1
αp3 − γ(I)
+ α(I)p2
2∑
i=1
p
(I)
i
λi + γ(I)
[
1
αp3 − γ(I)
− 1
αp3 + λi
]
− α
(A)
p2 env
0
A
αp3 − γ(A)
− α
(A)
p2 p
(A)
0
αp3γ
(A)
+
α
(A)
p2 p
(A)
0
γ(A)
1
αp3 − γ(A)
+ α(A)p2
2∑
i=1
p
(A)
i
λi + γ(A)
[
1
αp3 − γ(A)
− 1
αp3 + λi
]
(161)
r
(I)
2 =
env0Iα
(I)
p2
αp3 − γ(I)
− α
(I)
p2 p
(I)
0
γ(I)
1
αp3 − γ(I)
− α
(I)
p2
αp3 − γ(I)
2∑
i=1
p
(I)
i
λi + γ(I)
(162)
r
(A)
2 =
env0Aα
(A)
p2
αp3 − γ(A)
− α
(A)
p2 p
(A)
0
γ(A)
1
αp3 − γ(A)
− α
(A)
p2
αp3 − γ(A)
2∑
i=1
p
(A)
i
λi + γ(A)
(163)
r3i = α
(I)
p2
p
(I)
i
(λi + γ(I))(αp3 + λi)
+ α(A)p2
p
(A)
i
(λi + γ(A))(αp3 + λi)
(164)
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Other cases (e.g. γI = 0, γA = 0, αp3 = γ
I , αp3 = γ
A, etc. can be addressed
in a similar manner as necessary.
P24 equation
dP24
dt
+ γp2P24 = αp3Pr55 (165)
Using the result for Pr55 leads to the equation
dP24
dt
+ γp2P24 = αp3r0 + αp3r1e
−αp3 (t−t0) (166)
+ αp3r
(I)
2 e
−γ(I)(t−t0) + αp3r
(A)
2 e
−γ(A)(t−t0) + αp3
2∑
i=1
r3ie
λi(t−t0).
cases γp2 6= 0, γ(I) 6= 0, γ(A) 6= 0 and γp2 6= γ(I), γp2 6= γ(A)
Multiplying equation (165) through by the integrating factor eγp2 t leads to
d
dt
(
eγp2 (t−t
0)P24
)
= αp3r0e
γp2 (t−t0) + αp3r1e
(γp2−αp3 )(t−t0)
+ αp3r
(I)
2 e
(γp2−γ(I))(t−t0) + αp3r
(A)
2 e
(γp2−γ(A))(t−t0)
+ αp3
2∑
i=1
r3ie
(γp2+λi)(t−t0), (167)
Upon integrating and using P24(t
0) = P 024 we find
P24 = P
0
24e
−γp2 (t−t0) +
αp3r0
γp2
[
1− e−γp2 (t−t0)
]
+
αp3r1
γp2 − αp3
[
e−αp3 (t−t
0) − e−γp2 (t−t0)
]
+
αp3r
(I)
2
γp2 − γ(I)
[
e−γ
(I)(t−t0) − e−γp2 (t−t0)
]
+
αp3r
(A)
2
γp2 − γ(A)
[
e−γ
(A)(t−t0) − e−γp2 (t−t0)
]
+ αp3
2∑
i=1
r3i
γp2 + λi
[
eλi(t−t
0) − e−γp2 (t−t0)
]
(168)
Combining terms gives the solution
P24 = s0 + s1e
−γp2 (t−t0) + s2e−αp3 (t−t
0)
+ s
(I)
3 e
−γ(I)(t−t0) + s(A)3 e
−γ(A)(t−t0) +
2∑
i=1
s4ie
λi(t−t0), (169)
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where
s0 =
αp3r0
γp2
(170)
s1 = P
0
24 −
αp3r0
γp2
− αp3r1
γp2 − αp3
− αp3r
(I)
2
γp2 − γ(I)
− αp3r
(A)
2
γp2 − γ(A)
− αp3
2∑
i=1
r3i
γp2 + λi
(171)
s2 =
αp3r1
γp2 − αp3
(172)
s
(I)
3 =
αp3r
(I)
2
γp2 − γ(I)
(173)
s
(A)
3 =
αp3r
(A)
2
γp2 − γ(A)
(174)
s4i = αp3
r3i
γp2 + λi
. (175)
case γp2 = 0, γ
(I) 6= 0, γ(A) 6= 0
Here
dP24
dt
= αp3r0 + αp3r1e
−αp3 (t−t0)
+ αp3r
(I)
2 e
−γ(I)(t−t0) + αp3r
(A)
2 e
−γ(A)(t−t0)
+ αp3
2∑
i=1
r3ie
λi(t−t0). (176)
Integrating and applying P24(t
0) = P 024 gives
P24 = P
0
24 + αp3r0(t− t0)− r1
[
e−αp3 (t−t
0) − 1
]
− αp3r
(I)
2
γ(I)
[
e−γ
(I)(t−t0) − 1
]
− αp3r
(A)
2
γ(A)
[
e−γ
(A)(t−t0) − 1
]
+ αp3
2∑
i=1
r3i
λi
[
eλi(t−t
0) − 1
]
(177)
We can write this as
P24 = s0 + s1(t− t0) + s2e−αp3 (t−t0)
+ s
(I)
3 e
−γ(I)(t−t0) + s(A)3 e
−γ(A)(t−t0) +
2∑
i=1
s4ie
λi(t−t0), (178)
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where
s0 = P
0
24 + r1 +
αp3r
(I)
2
γ(I)
+
αp3r
(A)
2
γ(A)
− αp3
2∑
i=1
r3i
λi
(179)
s1 = αp3r0, (180)
s2 = −r1, (181)
s
(I)
3 = −
αp3r
(I)
2
γ(I)
, (182)
s
(A)
3 = −
αp3r
(A)
2
γ(A)
, (183)
s4i = αp3
r3i
λi
. (184)
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